Doliracetam

Doliracetam is a nootropic-type compound belonging by name to the racetam family, whose members share an acetamide group and have been investigated as potential cognition enhancers ^[1]. Its structure is based not on the pyrrolidinone ring of the classic racetams but on an oxindole, also called indolin-2-one, bearing a phenyl group and an acetamide side chain; its molecular formula is C16H14N2O2 ^[1]. The compound is catalogued in chemical databases but is not in common medical use ^[1].

The substance originates from a patent filed by the pharmaceutical company Hoechst AG, published in 1982, with Heinz Kuch and Hansjorg Kruse named as inventors ^[2]. That patent describes a series of indolinone-2 derivatives which, according to the document, possess neuroanabolic properties and favorably influence the metabolism of the brain, and it reports that the compounds improved the survival of animals subjected to low-oxygen conditions in laboratory testing ^[2]. Doliracetam is one member of this broad chemical class ^[2].

Beyond its patent origins and basic chemical characterization, doliracetam has attracted little scientific study, and it is not indexed in the biomedical research literature in the way that better-known racetams are ^[1]. It has not been approved or marketed as a medicine, and it carries no standard drug classification code ^[1]. Reflecting this obscurity, encyclopedic and database coverage of the compound is limited, and firm conclusions about its effects in humans cannot be drawn from the available information ^[1][2].

There is effectively no human safety data for doliracetam. The racetam class is generally tolerable, but that cannot be assumed for a compound this poorly studied. Sourcing and purity would be major concerns.

Doliracetam is a synthetic member of the racetam family, the class of pyrrolidinone derivatives that traces its origin to piracetam, first synthesized by Corneliu Giurgea in the 1960s. Doliracetam itself emerged from later pharmaceutical research; it is associated with the German company Hoechst, whose patent literature described the compound as having neuroanabolic activity and framed it as a candidate for the treatment of epilepsy and cognitive impairment. Like many racetam analogues developed during the industry's exploration of the scaffold, it was characterized primarily in the patent and early preclinical setting and did not advance to become a widely marketed medicine.

Doliracetam is one of the more obscure racetams and is little known even within nootropic circles. It has not accumulated a meaningful body of independent clinical research or a substantial base of user experience reports, and it is rarely offered by suppliers. Consequently it is regarded largely as a historical or investigational curiosity rather than a practical option, and commentators typically note that too little is known about its efficacy and safety in humans to make any confident recommendation.